Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc.

Biotechnology • Healthcare • Agoura Hills, CA, United States • OTLC (OQB)

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, it develops CA4P for the treatment of advanced metastatic melanoma; AL-101, an intranasal drug and delivery system for intra-nasal apomorphine for the treatment of parkinson's disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies, as well as nanoparticle products for the treatments of various cancers. The company is based in Agoura Hills, California.

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

IBN Initiates Coverage of Oncotelic Therapeutics Inc. - Yahoo Finance
Yahoo Finance • Sep 10
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating - GlobeNewswire
GlobeNewswire • Sep 18
Oncotelic Therapeutics CEO Discusses How Being LLM-Agnostic Gives It A Drug Development Edge - Benzinga
Benzinga • Dec 30
Oncotelic Therapeutics Launches PDAOAI Biomedical Data Platform - TipRanks
TipRanks • Dec 23
Oncotelic Therapeutics Signs Multiple Material Agreements - TradingView — Track All Markets
TradingView — Track All Markets • Dec 30

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Oncotelic Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Oncotelic Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Oncotelic Therapeutics, Inc. have?
Oncotelic Therapeutics, Inc. has approximately 26 employees.
What industry is Oncotelic Therapeutics, Inc. in?
Oncotelic Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Oncotelic Therapeutics, Inc. a publicly traded company?
Yes, Oncotelic Therapeutics, Inc. is publicly traded under the ticker symbol OTLC on the OQB. The company has a market capitalization of approximately $0.03 billion.
Where is Oncotelic Therapeutics, Inc. headquartered?
Oncotelic Therapeutics, Inc. is headquartered in Agoura Hills, CA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.